Chagas Disease Clinical Trial
Official title:
Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
Chagas disease is endemic to the Americas, infecting between 16-18 million individuals. In
immigrant populations in the United States from endemic areas, it is estimated up to 4.9% may
be asymptomatic carriers of Trypanosoma cruzi, the organism which causes Chagas disease.
Between 10-20% of these patients progress to development of end-stage cardiomyopathy with a
high associated morbidity. Following acute disease, patients enter into an indeterminate
phase which can last 10-20 years. The earliest sign of cardiac involvement usually is
electrocardiogram abnormalities. The most common abnormality is right bundle branch block
(RBBB), followed by left anterior fascicular block (LAFB), and left bundle branch block
(LBBB). Recent studies have shown that treatment of patients at this stage with
antiparasitics may delay the progression of overt cardiomyopathy.
At the University of California, Los Angeles, there is a large population of immigrant
patients from countries endemic to Chagas disease. The researchers propose that screening
patients with conduction abnormalities on electrocardiogram may be a potentially useful
method to identify patients with early cardiac manifestations of Chagas disease. The
researchers hope to enroll approximately 300 individuals with RBBB, LAFB or LBBB on
electrocardiogram to determine the incidence of Chagas disease in this patient population.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01162967 -
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
|
Phase 2 | |
| Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
| Active, not recruiting |
NCT04024163 -
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
|
Phase 3 | |
| Recruiting |
NCT05868005 -
Delivering a Multi-disease Screening Tool to Migrant Populations
|
N/A | |
| Completed |
NCT03892213 -
Pharmacokinetic Drug-Drug Interaction Study
|
Phase 1 | |
| Recruiting |
NCT00875173 -
Selenium Treatment and Chagasic Cardiopathy (STCC)
|
Phase 3 | |
| Recruiting |
NCT03704181 -
Colchicine for Patients With Chagas´ Disease( B1 Stage)
|
Phase 2 | |
| Active, not recruiting |
NCT03378661 -
BENDITA BEnznidazole New Doses Improved Treatment and Associations
|
Phase 2 | |
| Completed |
NCT01927224 -
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
|
Phase 1 | |
| Completed |
NCT01006486 -
Outcomes of an Anticoagulation Clinic in an University Hospital
|
Phase 4 | |
| Completed |
NCT00123916 -
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
|
Phase 3 | |
| Completed |
NCT02516293 -
Cardiac Rehabilitation in Chagas Heart Failure
|
Phase 2/Phase 3 | |
| Completed |
NCT02517632 -
Physical Exercise Program in Chronic Chagas Heart Disease
|
Phase 3 | |
| Recruiting |
NCT02099903 -
Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease
|
N/A | |
| Completed |
NCT01874795 -
Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure
|
N/A | |
| Completed |
NCT01006473 -
Exercise Training in Chagas Cardiomyopathy
|
Phase 4 | |
| Completed |
NCT02386358 -
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
|
Phase 3 | |
| Not yet recruiting |
NCT05477953 -
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
|
||
| Completed |
NCT02346123 -
Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy
|
N/A | |
| Recruiting |
NCT02295215 -
Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction
|
N/A |